Pregnant women with eczema needed for safety study on common cream
NCT ID NCT06259669
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows about 958 pregnant women with mild to moderate eczema (atopic dermatitis) who use ruxolitinib cream (Opzelura) and compares them to similar women who do not use the cream. Researchers track birth defects and other pregnancy outcomes to see if the cream is linked to any problems. The goal is to gather real-world safety data, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib cream (Opzelura)
What this could lead to
If this study shows no increased risk of birth defects, it could provide reassurance about using ruxolitinib cream during pregnancy.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove safety. Results may be influenced by other factors, and the study is still recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Syneos Health (remote site)
RECRUITINGMorrisville, North Carolina, 27560, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••